Histoindex Pte Ltd – Trademark Portfolio
Entity Type: 99
Histoindex Pte Ltd holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 5 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include QFIBS, GENESIS, FIBROSIGHT, HISTOINDEX, and QSTEATOSIS. The owner is based in Singapore.
20 SCIENCE PARK ROAD, #01-26/27
TELETECH PARK
Singapore 117674 , SG
Showing of trademarks Trademarks
Trademark Classifications
Histoindex Pte Ltd's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Histoindex Pte Ltd have?
Histoindex Pte Ltd has 10 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 abandoned, 2 cancelled.
What trademark classes does Histoindex Pte Ltd file in?
Histoindex Pte Ltd files trademarks across 3 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Histoindex Pte Ltd's most well-known trademarks?
Histoindex Pte Ltd's registered trademark portfolio includes well-known marks such as QFIBS, GENESIS, FIBROSIGHT, HISTOINDEX, and QSTEATOSIS. These are among 6 currently registered trademarks in the portfolio.
What is Histoindex Pte Ltd's trademark registration success rate?
Histoindex Pte Ltd has a 60% trademark registration rate, with 6 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.